Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans - PubMed (original) (raw)
Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans
Ping Yi et al. Drug Metab Dispos. 2010 Apr.
Abstract
Semagacestat is a functional gamma-secretase inhibitor that has been shown to reduce the rate of formation of amyloid-beta in vitro and in vivo. This study was conducted to characterize the disposition of semagacestat in humans. After a single 140-mg dose of [(14)C]semagacestat administered as an oral solution to six healthy male subjects, semagacestat was rapidly absorbed (T(max) approximately 0.5 h) and eliminated from the systemic circulation (terminal t(1/2) approximately 2.4 h). The major circulating metabolites of semagacestat, M2 (hydrolysis of the amide bond proximal to the benzazepine ring) and M3 (benzylic hydroxylation of the benzazepine ring), accounted for approximately 27 and 10% of total radioactivity exposure, respectively, as calculated from relative area under the plasma concentration versus time curve from 0 to 24 h derived from the plasma radiochromatograms. The radioactive dose was almost completely recovered after 7 days postdose, with 87% of the dose in urine and 8% in feces. Unchanged [(14)C]semagacestat in urine accounted for approximately 44% of the dose, which indicates that renal excretion played an important role in elimination. Metabolites M2 and M3, with their related secondary metabolites, each accounted for approximately 20% of the dose in excreta. In vitro data indicate the formation of M3 is primarily mediated by CYP3A, with cDNA-expressed CYP3A5 approximately 2 times more efficient than CYP3A4 in forming M3. Thus, the relative content of CYP3A4 and CYP3A5 in humans will likely determine the formation clearance of M3 after exposure to semagacestat.
Similar articles
- The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.
Ayan-Oshodi MA, Willis BA, Annes WF, Lowe SL, Friedrich S, de la Peña A, Zhang W, Brown T, Wise SD, Hall SD. Ayan-Oshodi MA, et al. Drug Metab Dispos. 2012 Oct;40(10):1945-52. doi: 10.1124/dmd.112.046060. Epub 2012 Jul 12. Drug Metab Dispos. 2012. PMID: 22789530 Clinical Trial. - Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants.
Willis BA, Zhang W, Ayan-Oshodi M, Lowe SL, Annes WF, Sirois PJ, Friedrich S, de la Peña A. Willis BA, et al. J Clin Pharmacol. 2012 Jun;52(6):904-13. doi: 10.1177/0091270011407195. Epub 2011 Jul 1. J Clin Pharmacol. 2012. PMID: 21724950 Clinical Trial. - Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.
Waldmeier F, Glaenzel U, Wirz B, Oberer L, Schmid D, Seiberling M, Valencia J, Riviere GJ, End P, Vaidyanathan S. Waldmeier F, et al. Drug Metab Dispos. 2007 Aug;35(8):1418-28. doi: 10.1124/dmd.106.013797. Epub 2007 May 17. Drug Metab Dispos. 2007. PMID: 17510248 Clinical Trial. - Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S, Miura M, Toriumi C, Satoh Y, Ooie T. Ohmori S, et al. Drug Metab Dispos. 2007 Sep;35(9):1624-33. doi: 10.1124/dmd.107.016030. Epub 2007 Jun 13. Drug Metab Dispos. 2007. PMID: 17567733 Clinical Trial. - Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.
Henley DB, May PC, Dean RA, Siemers ER. Henley DB, et al. Expert Opin Pharmacother. 2009 Jul;10(10):1657-64. doi: 10.1517/14656560903044982. Expert Opin Pharmacother. 2009. PMID: 19527190 Review.
Cited by
- γ-Secretase Inhibitors Selected by Molecular Docking, to Develop a New Drug Against Alzheimer's Disease.
Trasviña-Arenas CH, Ayala Medina LA, Vique-Sánchez JL. Trasviña-Arenas CH, et al. Rep Biochem Mol Biol. 2023 Jul;12(2):340-349. doi: 10.61186/rbmb.12.2.340. Rep Biochem Mol Biol. 2023. PMID: 38317814 Free PMC article. - Neuropathological and biochemical assessments of an Alzheimer's disease patient treated with the γ-secretase inhibitor semagacestat.
Roher AE, Maarouf CL, Kokjohn TA, Whiteside CM, Kalback WM, Serrano G, Belden C, Liebsack C, Jacobson SA, Sabbagh MN, Beach TG. Roher AE, et al. Am J Neurodegener Dis. 2014 Dec 5;3(3):115-33. eCollection 2014. Am J Neurodegener Dis. 2014. PMID: 25628963 Free PMC article. - Alzheimer's disease: which type of amyloid-preventing drug agents to employ?
Jang H, Connelly L, Arce FT, Ramachandran S, Lal R, Kagan BL, Nussinov R. Jang H, et al. Phys Chem Chem Phys. 2013 Jun 21;15(23):8868-77. doi: 10.1039/c3cp00017f. Epub 2013 Feb 28. Phys Chem Chem Phys. 2013. PMID: 23450150 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources